57 Results
New Insights into HIV Latent Cells Yield Potential Cure Targets
July 27, 2022
Scientists with the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) and their collaborators described how their use of cutting-edge technology revealed new insights into cellular reservoirs of HIV and what those observations could mean for the next steps in HIV cure research.
Combination Anti-HIV Antibody Infusions Suppress Virus for Prolonged Period
June 1, 2022
According to a small study published today in the journal Nature, individuals with HIV who began taking antiretroviral therapy (ART) in the early stages of infection achieved a lengthy period of HIV suppression without ART after receiving two broadly neutralizing anti-HIV antibodies (bNAbs).
Statement—NIH Celebrates FDA Approval of Long-Acting Injectable Drug for HIV Prevention
December 21, 2021
U.S. Food and Drug Administration announced its first approval of a long-acting HIV prevention medication. Developed by ViiV Healthcare, the medicine is long-acting cabotegravir injected once every two months. FDA has approved the medicine for use by adults and adolescents weighing at least 35 kilograms who are at risk of sexually acquiring HIV.
Experimental mRNA HIV Vaccine Safe, Shows Promise in Animals
December 9, 2021
An experimental HIV vaccine based on mRNA—the same platform technology used in two highly effective COVID-19 vaccines—shows promise in mice and non-human primates, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
NIH Researchers Identify How Two People Controlled HIV After Stopping Treatment
October 28, 2021
Research led by scientists at the National Institutes of Health has identified two distinct ways that people with HIV can control the virus for an extended period after stopping antiretroviral therapy (ART) under medical supervision. This information could inform efforts to develop new tools to help people with HIV put the virus into remission without taking lifelong medication, which can have long-term side-effects.
Antibody Infusions Prevent Acquisition of Some HIV Strains, NIH Studies Find
January 26, 2021
NIH finds that an investigational anti-HIV antibody prevented acquisition of some HIV strains, but did not significantly reduce overall acquisition.
Leadership Transition at the NIAID Vaccine Research Center
February 16, 2022
Dr. Fauci expresses gratitude to John R. Mascola, M.D., as he announces his retirement as Director of the Dale and Betty Bumpers Vaccine Research Center at the National Institute of Allergy and Infectious Diseases.